Clinical trials: Alzheimer's
Alzheimer's Disease
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.
- Trial name
- CONCERT (NCT00829374)
- Testing
- Dimebon
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 1,003 people
- Sponsor
- Medivation, Inc.
Alzheimer's Disease
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
Multi-centre study of HTL0018318 in patients with Alzheimer's disease as an add-on to standard-of-care
- Trial name
- NCT03456349
- Testing
- HTL0018318
- Where
- 4 sites in Czechia, Poland and 2 more
- Volunteers
- 60 people
- Sponsor
- Nxera Pharma UK Limited
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Alzheimer Disease
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up to 332 weeks.
- Trial name
- NCT05026866
- Testing
- Donanemab
- Where
- 216 sites in United States, Japan and 1 more
- Volunteers
- 2,996 people
- Sponsor
- Eli Lilly and Company
Alzheimer´s Disease
Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease
This study examines the long term Safety Follow-up of first patients vaccinated with AD02.
- Trial name
- NCT01357629
- Where
- 2 sites in Austria
- Volunteers
- 11 people
- Sponsor
- Affiris AG
Alzheimer's Disease
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as…
- Trial name
- EMERGE (NCT02484547)
- Testing
- Aducanumab (BIIB037)
- Where
- 180 sites in United States, Belgium and 11 more
- Volunteers
- 1,643 people
- Sponsor
- Biogen
Alzheimer's Disease
16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
To investigate the efficacy of Exelon capsule at maximal tolerated dose in mild to moderate Chinese AD patients via dosage titration from 3mg/d to 12mg/d in a 16 weeks duration
- Trial name
- INSTINCT (NCT01948791)
- Testing
- ENA713
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Drug Interaction Study With a Potential Alzheimer's Disease Compound
The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan
- Trial name
- NCT00726726
- Testing
- Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease
Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.
A long-term follow-up study to obtain safety and efficacy data in subjects who completed phase 1/2a clinical trial of NEUROSTEM® (NCT02054208), comparing NEUROSTEM and placebo groups for up to 36 months after the initial…
- Trial name
- NCT03172117
- Testing
- human umbilical cord blood derived mesenchymal stem cells, Normal saline 2mL
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Medipost Co Ltd.
Cognitive Impairments, Alzheimer Disease
Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment
The aim of the study is to evaluate the beneficial effect of a mixture of vegetal oils with a composition related to short, medium and long unsaturated chain fatty acids on patients with a diagnose of cognitive impairment or mild…
- Trial name
- NCT02778581
- Testing
- Lipidic Blend 1, Lipidic Blend 2
- Where
- 2 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Team Foods Colombia S.A.
Alzheimer Disease, Late Onset
BCG and Plasma Amyloid in Non-Demented Adults
BCG vaccination, the most widely used vaccination in the world, is used to reduce risk of tuberculosis infection; it is used for other mycobacterial infections as well, benefiting leprosy and Buruli ulcer.
- Trial name
- NCT04449926
- Testing
- Bacillus of Calmette and Guerin (BCG)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Mindful Diagnostics and Therapeutics, LLC
Dementia, Alzheimer's Disease
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
To Determine the the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral β-Amyloid When Compared With Postmortem Histopathology
- Trial name
- NCT01886820
- Testing
- [18F]NAV4694
- Where
- 15 sites in United States
- Volunteers
- 290 people
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer's Disease
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01369225
- Testing
- AAB-003 (PF-05236812)
- Where
- 21 sites in United States, South Korea
- Volunteers
- 52 people
- Sponsor
- Pfizer
Dementia, Alzheimer Disease
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.
- Trial name
- NCT00216593
- Testing
- galantamine hydrobromide
- Volunteers
- 415 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
This study consists of two parts, Part 1 and Part 2. Part 1 assesses the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI)…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- APECS (NCT01953601)
- Testing
- Verubecestat 12 mg (Parts 1 and 2), Verubecestat 40 mg (Parts 1 and 2)
- Volunteers
- 1,454 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
SB-742457 And Donepezil In Alzheimer's Disease
The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease.
- Trial name
- NCT00348192
- Testing
- SB-742457, donepezil
- Where
- 26 sites in Austria, Bulgaria and 6 more
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
- Trial name
- AMBAR (NCT01561053)
- Testing
- Albumin 5%, Albumin 20%, Immunoglobulin
- Where
- 40 sites in United States, Spain
- Volunteers
- 347 people
- Sponsor
- Instituto Grifols, S.A.
Alzheimer Disease, Mild Cognitive Impairment
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants.
- Trial name
- 2-HOBA (NCT06432166)
- Testing
- 2-hydroxybenzylamine acetate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- MTI Biotech Inc
Alzheimer's Disease
Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients
Primary Objective: To assess the safety and tolerability of escalating single and multiple doses of SAR228810 in patients with Alzheimer's disease (AD) Secondary Objective: To evaluate the pharmacokinetic properties of SAR228810…
- Trial name
- NCT01485302
- Testing
- SAR228810
- Where
- 8 sites in Bulgaria, France and 3 more
- Volunteers
- 48 people
- Sponsor
- Sanofi
Alzheimer Disease
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD.
- Trial name
- NCT06566170
- Testing
- Donanemab, Usual Care
- Where
- United States
- Volunteers
- 6,250 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.